TREATMENT OF DEPENDENCE WITHDRAWAL
    20.
    发明公开
    TREATMENT OF DEPENDENCE WITHDRAWAL 有权
    BEHANDLUNG VON ENTZUG

    公开(公告)号:EP1646328A4

    公开(公告)日:2006-08-30

    申请号:EP04779186

    申请日:2004-07-26

    申请人: EURO CELTIQUE SA

    摘要: Dosage regimens of buprenorphine to treat withdrawal or abstinence syndrome in a drug dependent or opioid tolerant patient who is pregnant are described. The method includes treating withdrawal or abstinence syndrome of the patient by transdermal administration of an amount of buprenorphine effective to reduce withdrawal symptoms. For example, a first buprenorphine-containing transdermal dosage form can be administered for a first dosing period that is no more than about 5 days; a second buprenorphine-containing transdermal dosage form for a second dosing period that is no more than about 5 days, the second dosage form comprising the same or a greater dosage of buprenorphine than the first dosage form; and a third buprenorphine-containing transdermal dosage form for a third dosing period that is at least 2 days, the third dosage form comprising the same or a greater dosage of buprenorphine than the second dosage form.

    摘要翻译: 描述了丁丙诺啡的剂量方案以治疗怀孕的药物依赖或阿片耐受患者的戒断或戒断综合征。 该方法包括通过透皮施用有效减少戒断症状的量的丁丙诺啡来治疗患者的戒断或戒断综合征。 例如,第一次含有丁丙诺啡的透皮剂型可以在不超过约5天的第一次给药期内给药; 第二剂量的丁丙诺啡的透皮剂型持续不超过约5天,第二剂型包含与第一剂型相同或更高剂量的丁丙诺啡; 和第三次含有丁丙诺啡的透皮剂型,持续至少2天的第三次给药期,所述第三剂型包含与第二剂型相同或更大剂量的丁丙诺啡。